Comparing two tests for cervical cancer detection
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial compares a liquid-based cytology test with a molecular screening test to find early changes in the cervix that could lead to cancer. It may help you understand which test is better at detecting these changes before they become serious.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally healthy and between 18 and 85 years old.
- You must not eat for at least 6 hours and no more than 12 hours before the test.
- You need to avoid sexual activity for 24 hours before the study.
- You cannot be pregnant or think you might be pregnant.
- You have not had a hysterectomy (surgery to remove the uterus).
- You are not currently on chemotherapy, radiation, or other cancer treatment.
- You do not have HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new, non-invasive way to screen for cervical cancer. It uses a photoelectric device and an epigenetic test done on a sample from your cervix. The goal is to find early signs of cancer more accurately than current methods.
This study tests if a self-collected sample for HPV testing works as well as standard colposcopy to prevent cervical cancer. If you've recently had an abnormal cervical cancer screening and need a colposcopy, this trial may be an option for you.
This trial tests two cervical screening approaches to find early signs of HPV-related changes. It may help by improving how results are sorted into “needs follow-up” versus “routine care,” especially for women with different HPV patterns.
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
This study checks whether “liquid biopsies” (blood tests that look for cancer-related signals) can help monitor how HPV-related cancers respond to treatment. It may help doctors spot changes earlier during care.
This study follows women with an early abnormal cervix cell change (CIN2/CIN2-3) to see how HPV DNA “integration” relates to whether the condition improves or worsens. It may help doctors better predict prognosis and guide safer monitoring, especially if you want to become pregnant.
Hear when a new I) Atypical Squamous Cells of Undetermined Significance (ASC-US) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.